SangMu Jun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
SangMu Jun has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ahoua Yapi
Institut National de la Santé Public, Abidjan, Côte d’Ivoire
1 shared publication - Daria S. Khramova
Institute of Physiology of Federal Research Centre “Komi Science Centre of the Urals Branch of the Russian Academy of Sciences” Syktyvkar Russia
1 shared publication - David W. Pascual
College of Veterinary Medicine, University of Florida, Gainesville, FL
1 shared publication - Igor A. Schepetkin
Department of Plant Science and Plant Pathology, Montana State University, Bozeman, MT 59717, USA
1 shared publication - Koffi Kouakou
UFR Biosciences, Université Félix Houphouët-Boigny, Abidjan, Côte d’Ivoire
1 shared publication - Liliya N. Kirpotina
Department of Microbiology and Cell Biology, Montana State University, Bozeman, MT 59717, USA
1 shared publication
Latest Publications
- Open Access
- 28 June 2013
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 13 (1) , 149
Immunomodulatory activity of polysaccharides isolated from Clerodendrum splendens: Beneficial effects in experimental autoimmune encephalomyelitis
Background: Extracts of leaves fromClerodendrumhave been used for centuries to treat a variety of medicinal problems in tropical Africa. However, little is known about the high-molecular weight active components conferring therapeutic properties to these extracts.Methods: Polysaccharides from the leaves ofClerodendrum splendenswere extracted and fractionated by ion exchange and size-exclusion chromatography. Molecular weight determination, sugar analysis, degree of methyl esterification, and other chemical characterization of the fractions were performed. Immunomodulatory activity of the fractions was evaluated by determining their ability to induce monocyte/macrophage nitric oxide (NO), cytokine production, and mitogen-activated protein kinase (MAPK) phosphorylation. Experimental autoimmune encephalomyelitis (EAE) was induced in C57BL/6 mice, and severity of EAE was monitored in mice treated with intraperitoneal (i.p.) injections of the most active polysaccharide fraction. Lymph nodes (LN) and spleen were harvested, and levels of cytokines in supernatants from LN cells and splenocytes challenged with myelin oligodendrocyte glycoprotein peptide were determined.Results: Fractions containing type II arabinogalactan had potent immunomodulatory activity. Specifically, the high-molecular weight sub-fractionCSP-AU1(average of 38.5 kDa) induced NO and cytokine [interleukin (IL)-1α, -1β, -6, -10, tumor necrosis factor (TNF; designated previously as TNF-α), and granulocyte macrophage-colony stimulating factor (GM-CSF)] production by human peripheral blood mononuclear cells (PBMCs) and monocyte/macrophages.CSP-AU1-induced secretion of TNF was prevented by Toll-like receptor 4 (TLR4) antagonist LPS-RS, indicating a role for TLR4 signaling. Treatment withCSP-AU1also induced phosphorylation of a number of MAPKs in human PBMC and activated AP-1/NF-κB.In vivotreatment of mice withCSP-AU1andCSP-NU1resulted in increased serum IL-6, IL-10, TNF, monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein (MIP)-1α/CCL3, and MIP-1β/CCL4.CSP-AU1treatment of mice with EAE (50 mg/kg,i.p., daily, 13 days) resulted in significantly reduced disease severity in this experimental model of multiple sclerosis. Levels of IL-13, TNF, interferon (IFN)-γ, IL-17, and GM-CSF were also significantly decreased, whereas transforming growth factor (TGF)-β was increased in LN cells fromCSP-AU1-treated EAE mice.Conclusions: PolysaccharideCSP-AU1is a potent natural innate immunomodulator with a broad spectrum of agonist activityin vitroand immunosupressive properties after chronic administrationin vivo.
- 28 June 2013
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 13 (1) , 149
Open AccessImmunomodulatory activity of polysaccharides isolated from Clerodendrum splendens: Beneficial effects in experimental autoimmune encephalomyelitis
Background: Extracts of leaves fromClerodendrumhave been used for centuries to treat a variety of medicinal problems in tropical Africa. However, little is known about the high-molecular weight active components conferring therapeutic properties to these extracts.Methods: Polysaccharides from the leaves ofClerodendrum splendenswere extracted and fractionated by ion exchange and size-exclusion chromatography. Molecular weight determination, sugar analysis, degree of methyl esterification, and other chemical characterization of the fractions were performed. Immunomodulatory activity of the fractions was evaluated by determining their ability to induce monocyte/macrophage nitric oxide (NO), cytokine production, and mitogen-activated protein kinase (MAPK) phosphorylation. Experimental autoimmune encephalomyelitis (EAE) was induced in C57BL/6 mice, and severity of EAE was monitored in mice treated with intraperitoneal (i.p.) injections of the most active polysaccharide fraction. Lymph nodes (LN) and spleen were harvested, and levels of cytokines in supernatants from LN cells and splenocytes challenged with myelin oligodendrocyte glycoprotein peptide were determined.Results: Fractions containing type II arabinogalactan had potent immunomodulatory activity. Specifically, the high-molecular weight sub-fractionCSP-AU1(average of 38.5 kDa) induced NO and cytokine [interleukin (IL)-1α, -1β, -6, -10, tumor necrosis factor (TNF; designated previously as TNF-α), and granulocyte macrophage-colony stimulating factor (GM-CSF)] production by human peripheral blood mononuclear cells (PBMCs) and monocyte/macrophages.CSP-AU1-induced secretion of TNF was prevented by Toll-like receptor 4 (TLR4) antagonist LPS-RS, indicating a role for TLR4 signaling. Treatment withCSP-AU1also induced phosphorylation of a number of MAPKs in human PBMC and activated AP-1/NF-κB.In vivotreatment of mice withCSP-AU1andCSP-NU1resulted in increased serum IL-6, IL-10, TNF, monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein (MIP)-1α/CCL3, and MIP-1β/CCL4.CSP-AU1treatment of mice with EAE (50 mg/kg,i.p., daily, 13 days) resulted in significantly reduced disease severity in this experimental model of multiple sclerosis. Levels of IL-13, TNF, interferon (IFN)-γ, IL-17, and GM-CSF were also significantly decreased, whereas transforming growth factor (TGF)-β was increased in LN cells fromCSP-AU1-treated EAE mice.Conclusions: PolysaccharideCSP-AU1is a potent natural innate immunomodulator with a broad spectrum of agonist activityin vitroand immunosupressive properties after chronic administrationin vivo.